Crinetics Pharmaceuticals Inc
For the period ended Dec 31, 2023. Filed Feb 28, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 28, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Loss
Checking your notes…
(In thousands, except per share data)
| Revenues | $4,013 | $4,737 | $1,078 |
|---|---|---|---|
| Operating expenses: | |||
| Research and development | 168,527 | 130,225 | 84,255 |
| General and administrative | 58,094 | 42,394 | 24,525 |
| Total operating expenses | 226,621 | 172,619 | 108,780 |
| Loss from operations | (222,608) | (167,882) | (107,702) |
| Other income (expense): | |||
| Interest income | 13,436 | 4,317 | 157 |
| Change in fair value of derivative asset | — | 600 | — |
| Other income (expense), net | (159) | 57 | (96) |
| Total other income, net | 13,277 | 4,974 | 61 |
| Loss before equity method investment | (209,331) | (162,908) | (107,641) |
| Loss on equity method investment | (5,198) | (1,010) | — |
| Net loss | $(214,529) | $(163,918) | $(107,641) |
| Net loss per share: | |||
| Net loss per share - basic and diluted | $(3.69) | $(3.15) | $(2.80) |
| Weighted average shares - basic and diluted | 58,071 | 51,982 | 38,436 |
| Other comprehensive income (loss): | |||
| Unrealized gain (loss) on investment securities | $4,908 | $(3,549) | $(407) |
| Comprehensive loss | $(209,621) | $(167,467) | $(108,048) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.